Immunochemistry services director joins PharmaNet

Will expand large molecule services at US firm

Chris Beaver has joined PharmaNet Development Group, a US provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, as director of immunochemistry services.

Beaver will lead the immunochemistry team within the firm’s bioanalytical laboratories and expand its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

PharmaNet has two GLP-compliant bioanalytical laboratories located in Princeton, New Jersey and Quebec City, Canada.

You may also like

Manufacturing
The 7 most common process development mistakes

The 7 most common process development mistakes

At laboratory scale, processes may appear predictable, repeatable, and well understood. However this perceived level of control can be misleading
Manufacturing
What are injectable hydrogel microspheres?

What are injectable hydrogel microspheres?

The demand for longer-lasting therapies is accelerating innovation in injectable drug delivery, driven by the need to maintain stable therapeutic levels while minimising repeated administration
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
What Operation TrialBlazer means for CDMOs and CMC strategy

What Operation TrialBlazer means for CDMOs and CMC strategy

The FDA's new framework cuts Phase I data requirements, opens platform manufacturing data reuse and creates a new CRO/CDMO review role as HHS moves to close the gap with China's faster clinical trial pipeline — but how will this affect the pharma sector?
Manufacturing
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions highlights strong performance across more than 200 customer audits

Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Manufacturing
TurboFil introduces Benchtop Version of Precision Unidose and Bi-dose Vial Filler and Stoppering System

TurboFil introduces Benchtop Version of Precision Unidose and Bi-dose Vial Filler and Stoppering System

Company’s manual UDS/BDS Benchtop Vial Filler utilises same technique as its higher-volume automatic systems, simplifying lab-scale filling while easing downstream scale-up
Subscribe now